Publishing giant Macmillan buys Israeli start-up

BioData Ltd. has been acquired by Macmillan Publishers Ltd in deal worth $5 million to $10m.

January 3, 2011 22:41
2 minute read.
The Jerusalem Post

laboratory 311. (photo credit: Bloomberg)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Israeli start-up BioData Ltd. has been acquired by Macmillan Publishers Ltd. The deal is worth $5 million to $10m. for more than half of BioData’s shares, reflecting a company value of up to $20, people familiar with the matter told Globes. BioData declined to comment on the figure.

Macmillan, which publishes Nature and Scientific American, is seeking to expand into new fields. The acquisition of Bio-Data is part of its new venture, Digital Science, which is aimed at providing world-class software tools and services to scientists, managers and investors to make their research more productive through the use of technology.

Be the first to know - Join our Facebook page.

BioData CEO Jonathan Gross founded the company in 2007 and financed it with help from his friends and family. “We had sales from day one,” he told Globes.

BioData’s primary market is Israel, and it has some international activity. Customers include thousands of laboratories, where hundreds of thousands of students use its software.

Macmillan is one of the world’s largest publishing houses. In addition to its journals in the natural and social sciences, and popular science magazines, it publishes textbooks and literature, academic literature and has academic information sites.

“Scientific research is at the beginning of a transformative digital age, and BioData is one of a breed of new companies that will be powering it,” Digital Science managing director Timo Hannay said.

When Digital Science was launched last month, Hannay said: “Research is becoming more and more digitally enabled and hence more productive, but the gap between the potential opportunity and the current state of the art is still wide. For example, we still have better tools for managing our personal music and photo collections than we have for managing, tracking and mining professional scientific information. At Digital Science we want to help change that.”


Digital Science also announced commercial partnerships with SureChem Inc. of the US and Symplectic Ltd. of the UK. Digital Science learned about BioData during its negotiations with Symplectic, which had earlier considered collaborating with BioData.

“The negotiations with Digital Science were not always simple, because it’s a large company and we’re a small Israeli start-up,” Gross said. “Nevertheless, the atmosphere was pleasant. They spoke our language and, like us, they know what researchers need. It was much easier for us to explain our product to them than to venture-capital funds, for example, which is also why BioData didn’t raise capital from them, although we considered it.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection